CD4 T cells kill melanoma cells by mechanisms that are independent of fas (CD95)

International Journal of Cancer

Volumn 75, Issue 3, 1998, Pages 384-390

  Thomas, Wavne D ^a   Hersey, Peter ^a,b  

^a JOHN HUNTER HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; HLA ANTIGEN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CONTROLLED STUDY; HELPER CELL; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA CELL; PRIORITY JOURNAL;

ANTIGENS, CD95; APOPTOSIS; BASE SEQUENCE; CALCIUM; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032579233     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980130)75:3<384::AID-IJC10>3.0.CO;2-9     Document Type: Article

References (29)

1. ALDERSON, M.R., TOUGH, T.W., DAVIS-SMITH, T., BRADDY, S., FALK, B., SCHOOLEY, K.A., GOODWIN, R.G., SMITH, C.A., RAMSDELL, F. and LYNCH, D.H., Fas ligand mediates activation-induced cell death in human T lymphocytes. J. exp. Med., 181, 71-77 (1995).
2. BARINGA, M., Forging a path to cell death. Science, 273, 735-737 (1996).
3. CASCINO, I., PAPOFF G., DE MARIA, R., TESTI, R. and RUBERTI, G., Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol., 156, 13-17 (1996).
4. + T-cell clones from regional lymph nodes of melanoma patients, Int. J. Cancer, 51, 218-224 (1992).
5. DARMON, A.J., EHRMAN, N., CAPUTO, A., FUJINAGA, J. and BLEACKLEY, R.C., The cytotoxic T cell proteinase granzyme B does not activate interleukin-1 beta-converting enzyme. J. biol. Chem., 269, 32043-32046 (1994).
6. DARMON, A.J., NICHOLSON, D.W. and BLEACKLEY, R.C., Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature (Lond). 377, 446-448 (1995).
7. ENARI, M., TALANIAN, R.V., WONG, W.W. and NAGATA, S,. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature (Lond.), 380, 723-726 (1996).
8. GOLSTEIN, P., QJCIUS, D.M. and YOUNG, J.D.-E., Cell death mechanisms and the immune system. Immunol. Rev., 121, 29-65 (1991).
9. + T cell responses to tumors. In: M.T. Lotze and O.J. Finn (eds.) Cellular immunity and the immunotherapy of cancer, pp. 235-242, Wiley-Liss, New York (1990).
10. GREENBERG, P., WATANABE, K., GILBERT, M., NELSON, B. and RIDDELL, S., Reconstruction of viral immunity in immunocompromised humans by the adoptive transfer of T cell clones. J. cell Biochem., Suppl. 17D, 99 (1993).
11. HAHNE, M., RIMOLDI, D., SCHROTER, M., ROMERO, P., SCHREIER, M., FRENCH, L.E., SCHNEIDER, P. BORNAND, T., FONTANA, A., LIÉNARD, D., CEROTTINI, J.-C. and TSCHOPP, J., Melanoma cell expression of Fas(Apo-l/ CD95) ligand; implications for tumor immune escape. Science, 274, 1363-1366 (1996).
12. HERSEY, P., MURRAY, E., GRACE, J. and MCCARTHY, W.H., Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma. Pathology, 17, 385-391 (1985).
13. 2+ antiport on susceptibility to eytolysin/ perforin-mediated cytolysis. J. Immunol., 144, 3498-3505 (1990).
14. + cytotoxic T-cell clones directed to autologous human melanoma identitied by cytokine profiles. Int. J. Cancer, 57, 56-62 (1994).
15. NGUYEN, T.D., SMITH, M.J. and MERSEY, P., Contrasting effects of T cell growth factors on T cell responses to melanoma in vitro. Cancer Immunol. Immunother., 43, 345-354 (1997).
16. O'CONNELL, J., O'SULLIVAN, G.C., COLLINS, J.K. and SHANAHAN, F., The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. exp. Med., 184, 1075-1082 (1996).
17. OEHM, A., BEHRMANN, I., FALK, W., PAWLITA, M., MAIER, G., KLAS, C., LI-WEBER, M., RICHARDS, S., DHEIN, J., TRAUTH, B.C., PONSTINGL, H. and KRAMMER, P.M., Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor supertumily. Sequence identity with the Fas antigen. J. biol. Chem., 267, 10709-10715 (1992).
18. OWEN-SCHAUB, L.B., RADINSKY, R., KRUZEL, E., BERRY, K. and YONCHARA, S., Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res., 54, 1580-1586 (1994).
19. OWEN-SCHAUH, L.B., YONEHARA, S., CRUMP, W.L. 3rd and GRIMM, E.A., DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell. Immunol., 140, 197-205 (1992).
20. PODACK, E.R. and KONIGSBERG, P.J., Cytolytic T cell granules. Isolation, structural, biochemical, and functional characterization. J. exp. Med., 160, 695-710 (1984).
21. RATHJEN, D.A., COWAN, K., FURPHY, L.J. and ASTON, R., Antigenic structure of human tumour necrosis factor: recognition of distinct regions of TNFα by different tumour cell receptors. Mol. Immunol. 28, 79-86 (1991).
22. + T cell-mediated cytotoxicity, J. Immunol., 152, 1127-1140 (1994).
23. STRASSER, A., Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Curr: Opin. Immunol., 7, 228-234 (1995).
24. + T lymphocytes against human melanoma. J. Immunol., 154, 772-779 (1995).
25. TEFANY, F.J., BARNETSON, R.ST.C., HALLIDAY, G.M., MCCARTHY, S.W. and MCCARTHY, W.H., Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J. invest. Dermatol., 97, 197-202 (1991).
26. TOPALIAN, S.L., GONZALES, M.I., PARKHURST, M., LI, Y.F., SOUTHWOOD, S., SETTE, A., ROSRNBERG, S.A. and ROBBINS, P.F., Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. exp. Med. 183, 1965-1971 (1996).
27. TRAUTH, B.C., KLAS, C., PETERS, A.M.J., MATZKU, S., MOLLER, P., FALK, W., DEBATIN, K.-M. and YONEHARA, M., Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science, 245, 301-305 (1989).
28. VERGELLI, M., HEMMER, B., MURARO, P.A., TRANQUILL, L., BIDDISON, W.E., SARIN, A., MCFARLAND, H.F. and MARTIN, R., Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. J. Immunol., 158, 2756-2761 (1997).
29. + CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J. Immunol., 156, 153-159 (1996).